Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Matsunaga, A. Hayata, T. Hirano, M. Ichinose (Wakayama, Japan). Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma. Eur Respir J 2012; 40: Suppl. 56, 2345

Member's Comments

No comment yet.

Related content which might interest you: Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 The prognostic value of extended lung function characterization in COPD Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020 Influence of β2-adrenoceptor genotype on risk of asthma worsening using fluctuation analysis of lung function Source: Eur Respir J 2007; 30: Suppl. 51, 447s Year: 2007 Combining exhaled-breath analysis data with clinical parameters to improve the diagnosis of lung cancer Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer Year: 2019 Non-invasive inflammatory markers can predict diagnosis, severity and stability of paediatric asthma Source: Eur Respir J 2006; 28: Suppl. 50, 122s Year: 2006 Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011 Novel lung function tests can improve phenotyping and differential therapy in COPD Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Consensus network analysis reveals pathways associated with lung function decline in both COPD and IPF Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006 Prognostic assessment in COPD without lung function: the B-AE-D indices Source: Eur Respir J 2016; 47:1635-1644 Year: 2016 Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Analysis of spontaneous breathing can predict abnormal lung function in asthma Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease Source: Eur Respir J, 58 (3) 2004133; 10.1183/13993003.04133-2020 Year: 2021 Novel method of expressing serum biomarkers profiling in COPD patients: The heatmap-clinical pattern profile Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Clinical relevance of small airways assessment by lung function tests in asthma Source: International Congress 2018 – Biomarkers and lung function in airway disease Year: 2018 Cluster analysis identifies distinct clinical phenotypes with poor treatment responsiveness in asthma. Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018